Table 4.
AI role in MASLD.
| AI | Author | Type of study | Study duration | Participants (n) | Comparator arm | Recruitment | Outcome | Ref |
|---|---|---|---|---|---|---|---|---|
| ANNa | Liu C et al | Cross-sectional | - | American people (6,613) | - | Predicting the risk of NAFLD | NAFLD was observed when the estimated risk of its occurrence exceeded the calculated threshold (0.388) using the established ANN model. | (28) |
| Path AI’s NASH MLb | Ratziu V et al | Randomized, double-blind, placebo-controlled trial | 72-week | NASH patient with confirmed biopsies (251) and fibrosis stage F1-F3 | Evaluated histological features of NASH by pathologists | Evaluating histological features of NASH | The agreement between AI and pathologists ranged from 0.28 to 0.62 weighted kappa statistics across histological characteristics. Steatosis (0.46–0.62) had the highest agreement, while fibrosis, lobular inflammation, and hepatocyte ballooning had lower. | (29) |
a. ANN: artificial neural network, b. ML: machine-learning.